SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:52d8bed0-a9a2-4d59-bdbf-64b4a7718625"
 

Search: onr:"swepub:oai:lup.lub.lu.se:52d8bed0-a9a2-4d59-bdbf-64b4a7718625" > Outcome and risk fa...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Outcome and risk factor analysis of molecular subgroups in cytogenetically normal AML treated by allogeneic transplantation.

Schmid, Christoph (author)
Labopin, Myriam (author)
Socié, Gerard (author)
show more...
Daguindau, Etienne (author)
Volin, Liisa (author)
Huynh, Anne (author)
Bourhis, Jean Henri (author)
Milpied, Noel (author)
Cornelissen, Jan (author)
Chevallier, Patrice (author)
Maertens, Johan (author)
Jindra, Pavel (author)
Blaise, Didier (author)
Lenhoff, Stig (author)
Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine
Ifrah, Norbert (author)
Baron, Frédéric (author)
Ciceri, Fabio (author)
Gorin, Claude (author)
Savani, Bipin (author)
Giebel, Sebastian (author)
Polge, Emmanuelle (author)
Esteve, Jordi (author)
Nagler, Arnon (author)
Mohty, Mohamad (author)
show less...
 (creator_code:org_t)
American Society of Hematology, 2015
2015
English.
In: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 126:17, s. 2062-2069
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Patients with cytogenetically normal acute myeloid leukemia (CN-AML) can be subdivided by molecular mutations. However, data on the influence of combinations of different aberrations on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) is limited. Therefore, we performed a retrospective registry analysis on 702 adults with CN-AML undergoing HSCT in first complete remission (CR). Patients were grouped according to presence or absence of NPM1 mutations (NPM1(mut)) and FLT3 internal tandem duplications (FLT3-ITD). Double negative patients were evaluated for mutations of the CCAAT/enhancer binding protein α gene (CEBPα). The influence of genotypes on relapse, non-relapse mortality, leukemia-free survival (LFS) and overall survival (OS), and a prognostic classification combining NPM1/FLT3-ITD profile and classical risk factors were calculated. 2y-OS from HSCT was 81±5% in NPM1(mut)/FLT3(wt) (n=68), 75±3% in NPM1(wt)/FLT3(wt) (n=290), 66±3% in NPM1(mut)/FLT3-ITD (n=269) and 54±7% in NPM1(wt)/FLT3-ITD (n=75; p=0.003). Analysis of CEBPα among patients with NPM1(wt)/FLT3(wt) revealed excellent results both in patients with CEBPα(mut) (n=13, 2y-OS:100%), and with a triple negative genotype (n=138, 2y-OS:77±3%). In a Cox-model of predefined factors, older age, presence of FLT3-ITD and >1 course of chemotherapy to reach CR were associated with inferior outcome. 2y-OS/LFS were 88±3%/79±4% in patients without any, 77±2%/73±3% with one, and 53±4%/50±4 with>=2 risk factors (p=0.002 for LFS, p=0.003 for OS). Hence, FLT3-ITD proofed to be the decisive molecular marker for outcome after HSCT for CN-AML in CR1, regardless of NPM1 mutational status, variations of transplant protocols, or development of GvHD. Age, FLT3-ITD and response to induction chemotherapy allow for a prognostic risk classification.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

  • Blood (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view